Scalable DSPE-KS-487 nanoformulation of KS-133 maintains brain penetration for schizophrenia cognitive impairment.
Background
Cognitive impairment is a core, debilitating symptom of schizophrenia with limited effective treatments. Hyperactivation of the VIPR2 (vasoactive intestinal peptide receptor 2) pathway is implicated in this cognitive dysfunction. The peptide KS-133, a VIPR2 antagonist, shows promise but requires a brain-penetrant delivery system. Previous nanoformulations using DPPE-KS-487 faced industrial scalability challenges due to complex manufacturing processes and the generation of positional isomers, hindering its clinical translation.
Study Design
Researchers developed a novel nanoformulation of KS-133 by encapsulating it in nanoparticles coated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-KS-487 (DSPE-KS-487). This new conjugate, produced via a non-click method, eliminated positional isomers and simplified manufacturing to a unidirectional ultrasonication process. The formulation's physical and chemical stability was assessed over time. Its brain penetration and therapeutic efficacy were evaluated in mice with VIPR2 agonist-induced novel object recognition impairment, comparing it to the previous DPPE-KS-487 formulation. Systemic toxicity was also assessed in mice receiving daily injections for two weeks at five times the effective dose.
Results
The novel DSPE-KS-487 nanoformulation of KS-133 demonstrated excellent stability, remaining physically and chemically stable for at least 12 months under refrigeration, with no changes in particle size, zeta potential, KS-133 content, or KS-487 presentation level. Critically, this improved formulation exhibited brain penetration and therapeutic efficacy against VIPR2 agonist-induced novel object recognition impairment in mice that was comparable to the previously reported DPPE-KS-487 nanoparticles. This indicates the new manufacturing process and DSPE conjugate did not compromise the therapeutic potential. Furthermore, a robust safety profile was observed: > No systemic side effects, including hematologic, brain, heart, liver, and lung toxicity, were detected following daily injections to mice for two weeks at five times the effective dose.
Key Findings
- New DSPE-KS-487 nanoformulation of KS-133 eliminates positional isomers and simplifies manufacturing.
- The improved formulation remained physically and chemically stable for at least 12 months under refrigeration.
- Brain penetration and efficacy against cognitive impairment in mice were comparable to the previous formulation.
- No systemic toxicity (hematologic, brain, heart, liver, lung) was detected after two weeks of daily injections at 5x effective dose.
Why It Matters
This improved nanoformulation of KS-133 addresses a critical bottleneck in its development: industrial scalability. By simplifying manufacturing and eliminating positional isomers, KS-133 becomes a more viable drug candidate for schizophrenia cognitive impairment. The maintained efficacy and strong safety profile at high doses in preclinical models suggest a promising path forward. This advancement brings a potential novel treatment for cognitive dysfunction in schizophrenia closer to clinical reality, offering a targeted approach to a symptom currently lacking effective therapies. The brain-penetrant shuttle mechanism could also be relevant for other neurological peptides.
ks-133
schizophrenia
cognitive-impairment
vipr2-antagonist
nanoformulation
brain-penetration